Long-term effect of imiglucerase in Latin American children with Gaucher disease type 1: lessons from the International Collaborative Gaucher Group Gaucher Registry
Conclusion
Continuous and long-term treatment with imiglucerase improves hematological, visceral and skeletal manifestations of Gaucher disease type 1.
Trial registration
NCT00358943.
Source: BMC Hematology - Category: Hematology Source Type: research
More News: Anemia | Children | Gaucher's Disease | Hematology | Hepatomegaly | Lessons | Liver | Pain | Thrombocytopenia | Urology & Nephrology